Trial Profile

A Phase 2a trial evaluating AQST-108 (epinephrine) Topical Gel in patients with alopecia areata (AA)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AQST 108 (Primary)
Indications Alopecia areata
Focus Therapeutic Use

Most Recent Events

20 Jan 2025 New trial record
13 Jan 2025 According to Aquestive Therapeutics media release company has successfully completed a pre-Investigational New Drug meeting with the FDA in December 2024 and remains on track to begin its Phase 2a trial in patients with alopecia areata (AA) in the second quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com